risankizumab IBD
Selected indexed studies
- Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. (JAMA, 2024) [PMID:39037800]
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. (N Engl J Med, 2024) [PMID:39018531]
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (Gastroenterology, 2024) [PMID:39572132]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. (2024) pubmed
- Therapeutic drug monitoring in inflammatory bowel disease: recent developments. (2024) pubmed
- Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. (2024) pubmed
- Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. (2024) pubmed
- Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years. (2025) pubmed
- Safety of Risankizumab during Pregnancy in IBD. (2026) pubmed
- Improving IBD outcomes in the era of many treatment options. (2023) pubmed
- Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. (2025) pubmed
- Guselkumab binding to CD64(+) IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling. (2025) pubmed
- Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study. (2026) pubmed